298 related articles for article (PubMed ID: 24605029)
21. Neurokinin-1 Receptor Antagonists against Hepatoblastoma.
Muñoz M; Rosso M; Coveñas R
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31466222
[TBL] [Abstract][Full Text] [Related]
22. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
23. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.
Muñoz M; González-Ortega A; Coveñas R
Invest New Drugs; 2012 Apr; 30(2):529-40. PubMed ID: 21120581
[TBL] [Abstract][Full Text] [Related]
24. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines.
Muñoz M; Rosso M; Robles-Frias MJ; Salinas-Martín MV; Rosso R; González-Ortega A; Coveñas R
Lab Invest; 2010 Aug; 90(8):1259-69. PubMed ID: 20458280
[TBL] [Abstract][Full Text] [Related]
25. Differential contribution of substance P and neurokinin A to spinal cord neurokinin-1 receptor signaling in the rat.
Trafton JA; Abbadie C; Basbaum AI
J Neurosci; 2001 May; 21(10):3656-64. PubMed ID: 11331395
[TBL] [Abstract][Full Text] [Related]
26. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus.
Ständer S; Yosipovitch G
Br J Dermatol; 2019 Nov; 181(5):932-938. PubMed ID: 31016733
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of substance P transport across the blood-brain barrier.
Chappa AK; Audus KL; Lunte SM
Pharm Res; 2006 Jun; 23(6):1201-8. PubMed ID: 16729222
[TBL] [Abstract][Full Text] [Related]
28. Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme.
Afshari AR; Motamed-Sanaye A; Sabri H; Soltani A; Karkon-Shayan S; Radvar S; Javid H; Mollazadeh H; Sathyapalan T; Sahebkar A
Curr Med Chem; 2021; 28(24):4877-4892. PubMed ID: 33441062
[TBL] [Abstract][Full Text] [Related]
29. Triple Negative Breast Cancer: How Neurokinin-1 Receptor Antagonists Could Be Used as a New Therapeutic Approach.
Muñoz M; Rosso M; Coveñas R
Mini Rev Med Chem; 2020; 20(5):408-417. PubMed ID: 31721701
[TBL] [Abstract][Full Text] [Related]
30. Uveal melanoma expresses NK-1 receptors and cyclosporin A induces apoptosis in human melanoma cell lines overexpressing the NK-1 receptor.
González-Ortega A; Sánchez-Vaderrábanos E; Ramiro-Fuentes S; Salinas-Martín MV; Carranza A; Coveñas R; Muñoz M
Peptides; 2014 May; 55():1-12. PubMed ID: 24548567
[TBL] [Abstract][Full Text] [Related]
31. Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms?
Adell A
Curr Drug Targets CNS Neurol Disord; 2004 Apr; 3(2):113-21. PubMed ID: 15078186
[TBL] [Abstract][Full Text] [Related]
32. NK-1 as a melanoma target.
Muñoz M; Bernabeu-Wittel J; Coveñas R
Expert Opin Ther Targets; 2011 Jul; 15(7):889-97. PubMed ID: 21592000
[TBL] [Abstract][Full Text] [Related]
33. The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines.
Rosso M; Robles-Frías MJ; Coveñas R; Salinas-Martín MV; Muñoz M
Tumour Biol; 2008; 29(4):245-54. PubMed ID: 18781096
[TBL] [Abstract][Full Text] [Related]
34. Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload.
Ge C; Huang H; Huang F; Yang T; Zhang T; Wu H; Zhou H; Chen Q; Shi Y; Sun Y; Liu L; Wang X; Pearson RB; Cao Y; Kang J; Fu C
Proc Natl Acad Sci U S A; 2019 Sep; 116(39):19635-19645. PubMed ID: 31488714
[TBL] [Abstract][Full Text] [Related]
35. SP/NK-1R promotes gallbladder cancer cell proliferation and migration.
Deng XT; Tang SM; Wu PY; Li QP; Ge XX; Xu BM; Wang HS; Miao L
J Cell Mol Med; 2019 Dec; 23(12):7961-7973. PubMed ID: 30903649
[TBL] [Abstract][Full Text] [Related]
36. A Substance P (SP)/Neurokinin-1 Receptor Axis Promotes Perineural Invasion of Pancreatic Cancer and Is Affected by lncRNA LOC389641.
Ji T; Ma K; Wu H; Cao T
J Immunol Res; 2022; 2022():5582811. PubMed ID: 35600049
[TBL] [Abstract][Full Text] [Related]
37. Substance P and neurokinin 1 receptors as potential therapeutic targets in children with OSA.
Gozal D; Kim J; Bhattacharjee R; Goldman JL; Kheirandish-Gozal L
Chest; 2014 May; 145(5):1039-1045. PubMed ID: 24356854
[TBL] [Abstract][Full Text] [Related]
38. Substance P Regulation in Epilepsy.
Chi G; Huang Z; Li X; Zhang K; Li G
Curr Neuropharmacol; 2018; 16(1):43-50. PubMed ID: 28474564
[TBL] [Abstract][Full Text] [Related]
39. The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer.
Rosso M; Muñoz M; Berger M
ScientificWorldJournal; 2012; 2012():381434. PubMed ID: 22545017
[TBL] [Abstract][Full Text] [Related]
40. Substance P and Neurokinin-1 Receptor System in Thyroid Cancer: Potential Targets for New Molecular Therapies.
Isorna I; González-Moles MÁ; Muñoz M; Esteban F
J Clin Med; 2023 Oct; 12(19):. PubMed ID: 37835053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
